Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclophosphamide
Drug ID BADD_D00549
Description Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Indications and Usage Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
Marketing Status approved; investigational
ATC Code L01AA01
DrugBank ID DB00531
KEGG ID D00287; D07760
MeSH ID D003520
PubChem ID 2907
TTD Drug ID D0CT9C
NDC Product Code 14335-360; 38779-0506; 10019-944; 10019-945; 10019-984; 58623-0024; 62559-931; 70121-1240; 0781-3233; 0781-3244; 10019-955; 51927-4871; 71052-223; 81955-0004; 43598-662; 50742-520; 69097-517; 70121-1239; 72572-085; 72572-087; 0781-3255; 10019-935; 10019-942; 51927-0221; 76339-191; 62332-619; 70121-1238; 54879-022; 55150-271; 62332-618; 69097-516; 70860-218; 42973-318; 10019-937; 76339-164; 50742-519; 51407-748; 72603-411; 10019-939; 65124-0003; 50742-521; 54879-021; 68001-564; 72603-326; 16714-857; 43598-661; 55150-270; 0054-0382; 10019-956; 10019-957; 51407-749; 51407-750; 68001-565; 0054-0383; 72572-083; 15308-0921; 10019-936; 57821-004; 16714-859; 68001-442; 68001-444; 72603-104; 10019-982; 82920-708; 16714-858; 46708-618; 68001-443; 10019-938; 10019-943; 57884-0022; 68554-0062; 43598-660; 46708-619
UNII 8N3DW7272P
Synonyms Cyclophosphamide | Sendoxan | B-518 | B 518 | B518 | Cyclophosphamide Anhydrous | Cyclophosphamide, (R)-Isomer | Cyclophosphamide, (S)-Isomer | Cytophosphane | Cyclophosphamide Monohydrate | Cytophosphan | Cytoxan | Endoxan | Neosar | NSC-26271 | NSC 26271 | NSC26271 | Procytox | (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate | Cyclophosphane
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 50-18-0
SMILES C1CNP(=O)(OC1)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachycardia02.03.02.007--Not Available
Telangiectasia23.06.03.001; 24.03.03.003--
Tenderness08.01.08.005--Not Available
Testicular atrophy21.13.01.001; 05.05.02.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Thrombotic microangiopathy24.01.01.013; 01.01.02.006; 20.01.07.004--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Tuberculosis11.04.01.006--Not Available
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Ulcer08.03.06.001--Not Available
Ureteric cancer20.06.01.008; 16.08.05.002--Not Available
Ureteric obstruction20.06.01.005--Not Available
Urine flow decreased20.02.02.012--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Uveitis10.02.01.023; 06.04.03.003--
Vasculitis24.12.04.027; 10.02.02.006--
Venoocclusive liver disease12.02.09.039; 24.04.07.002; 09.01.06.002--
Venous thrombosis24.01.01.008--Not Available
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene